Abstract 134P
Background
Cancer cells exhibit heightened basal levels of responses to DNA breaks, accumulating DNA polymerases family (DNA-pol) as repair protein, thereby increasing DNA mutation and neoantigens. Based on this, we investigated the potential of DNA-pol as an immunotherapy biomarker and its underlying mechanism.
Methods
We conducted a pan-cancer analysis of DNA-pol gene dysregulation in 6366 samples. Normal fibroblast, cancer-associated fibroblast, and CD8+ T cells were cultured from cancer patients (3 esophagus, 5 lung, 5 renal, and 3 liver cancer), then treated them with PD-L1 inhibitor or overexpressing TERT for RNA-seq and proteomics. 996 multiple cancer cases with ICIs were collected to test biomarker efficiency. A phase II clinical trial is evaluating our biomarker prospectively.
Results
We defined a distinct signature score of DNA-pol genes upregulated in cancer (DNA-pol-up) and linked to worse prognosis (HR=1.2). DNA-pol-up program dysregulation led to immune processes alteration and was related to upstream activation of TERT signaling (z-score=3.6) in ingenuity pathway analysis and linked to immunologically active tumors by recruiting CD8+ T cell and downregulating CAF. DNA-pol-up score was elevated in PD-L1-treated CAF and TERT-overexpressed CD8+ T cell, in MSI-H cancer, also related to more neoepitope peptides, TMB (Rho=0.54), cancer stemness (Rho=0.78), and tumor purity (Rho=0.29). Cancers that activate this program carried distinct genomic profiles with PIK3CA, KRAS, and TP53 mutations. This signature was an independent predictor for ICIs response (OR=2.52), even outperforming cytolytic activity, MSI, TMB (OR=0.9). In 12 clinical trial datasets, this signature could stratify the responding patients (maxAUC=0.762). In our phase II clinical trial, 34 liver cancer were enrolled with 3-year follow-up, it also has a satisfactory performance in predicting the ORR (AUC=0.699) and classifies mortality rate (HR=2.3).
Conclusions
Our findings identify a distinct transcriptional pattern of DNA-pol genes across cancers, which highlighted the role of DNA-pol family genes in predicting the immunotherapy response for the first time, and TERT could be a novel vaccine candidate for improving immunotherapy response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
X. Bi, H. Zhao, Z. Luo.
Funding
Zhiwen Luo was awarded a funding for research in Israel (China Scholarship Council No. 202106210312). CAMS Innovation Fund for Medical Sciences (CIFMS) (2021-I2M-C&T-B-043, 2021-I2M-C&T-B-052); Beijing CSCO Clinical Oncology Research Foundation (Y-XD202001-0111, Y-2019AZMS-0082, Y-XD202002-0370).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Presenter: M. S. Madhusudhan
Session: Poster session 01
228P - Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer
Presenter: Benjamin Haibe-Kains
Session: Poster session 01
230P - Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Presenter: Yohann Loriot
Session: Poster session 01
231P - Time to deterioration of quality of life as a surrogate of OS: A trial-level surrogacy analysis
Presenter: Adel Shahnam
Session: Poster session 01
232P - Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening?
Presenter: Alejandro Gallego Martinez
Session: Poster session 01